Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference

Core Viewpoint - Cocrystal Pharma, Inc. has announced that its pan-viral protease inhibitor CDI-988 will be presented at the International Calicivirus Conference, highlighting its potential as a treatment for norovirus infections, which currently lack approved antiviral therapies [1][2]. Group 1: Product Development - CDI-988 is a first-in-class oral treatment designed to inhibit noroviruses and coronaviruses, developed using Cocrystal's proprietary structure-based platform technology [3][6]. - The Phase 1 study of CDI-988 has been completed, focusing on safety, tolerability, and pharmacokinetics in healthy adults [3]. - The drug targets a highly conserved region in the active site of 3CL viral proteases, showcasing a novel mechanism of action and broad-spectrum antiviral activity [3][4]. Group 2: Market Context - Norovirus causes significant gastrointestinal illness with an estimated global societal cost of approximately $60 billion annually, according to the CDC [2]. - There are currently no approved vaccines or antiviral treatments for norovirus, indicating a substantial unmet medical need in this area [2]. Group 3: Conference Significance - The International Calicivirus Conference serves as a platform for leading experts in norovirus research, facilitating discussions and collaborations on advancements in the field [5]. - The conference will feature state-of-the-art lectures and presentations, providing an opportunity for Cocrystal to share its clinical development strategy and Phase 1 data for CDI-988 [2][5].